丛广志,贾绍斌

• 1:宁夏医科大学总医院心内科

摘要(Abstract)：

<正>慢性完全闭塞病变(chronic total occlusions,CTO)是指冠状动脉病变闭塞血管段前向TIMI血流0级,且闭塞时间至少超过3个月[1-2]。临床中18%~52%的非急诊冠状动脉造影表现为CTO[3-4]。有观察性研究显示,经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)开通CTO能够缓解缺血症状,减少室性心律失常,改

关键词(KeyWords)： 慢性完全闭塞病变;经皮冠状动脉介入治疗;优化药物治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 丛广志,贾绍斌

参考文献(References)：

• [1]Carlino M,Magri CJ,Uretsky BF,et al.Treatment of the chronic total occlusion:a call to action for the interventional community.Catheter Cardiovasc Interv,2015,85(5):771-778.
• [2]Sianos G,Werner GS,Galassi AR,et al.Recanalisation of chronic total coronary occlusions:2012 consensus document from the Euro CTO club.Euro Intervention,2012,8(1):139-145.
• [3]Fefer P,Knudtson ML,Cheema AN,et al.Current perspectives on coronary chronic total occlusions:the Canadian Multicenter Chronic Total Occlusions Registry.J Am Coll Cardiol,2012,59(11):991-997.
• [4]Jeroudi OM,Alomar ME,Michael TT,et al.Prevalence and management of coronary chronic total occlusions in a tertiary Veterans Affairs hospital.Catheter Cardiovasc Interv,2014,84(4):637-643.
• [5]Rossello X,Pujadas S,Serra A,et al.Assessment of inducible myocardial ischemia,quality of life,and functional status after successful percutaneous revascularization in patients with chronic total coronary occlusion.Am J Cardiol,2016,117(5):720-726.
• [6]张维.非劣效性临床试验的应用和注意点——美国食品和药物管理局(FDA)行业指南草案总结.中国药物评价,2012,29(5):369-371.
• [7]Sedlis SP,Hartigan PM,Teo KK,et al.Eff ect of PCI on long-term survival in patients with stable ischemic heart disease.N Engl J Med,2015,373(20):1937-1946.
• [8]Azzalini L,Jolicoeur EM,Pighi M,et al.Epidemiology,management strategies,and outcomes of patients with chronic total coronary occlusion.Am J Cardiol,2016,118(8):1128-1135.
• [9]Tomasello S D,Boukhris M,Giubilato S,et al.Management strategies in patients aff ected by chronic total occlusions:results from the Italian Registry of Chronic Total Occlusions.Eur Heart J,2015,36(45):3189-3198.
• [10]Jang WJ,Yang JH,Choi SH,et al.Long-term survival benefi t of revascularization compared with medical therapy in patients with coronary chronic total occlusion and well-developed collateral circulation.JACC Cardiovasc Interv,2015,8(2):271-279.
• [11]George S,Cockburn J,Clayton TC,et al.Long-term follow-up of elective chronic total coronary occlusion angioplasty:analysis from the U.K.Central Cardiac Audit Database.J Am Coll Cardiol,2014,64(3):235-243.
• [12]Maeremans J,Walsh S,Knaapen P,et al.The hybrid algorithm f or treating chronic total occlusions in Europe:the RECHARGE registry.J Am Coll Cardiol,2016,68(18):1958-1970.
• [13]Patel MR,Dehmer GJ,Hirshfeld JW,et al.ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update:a report of the American College of Cardiology Foundation appropriate use criteria task force,Society for Cardiovascular Angiography and Interventions,Society of Thoracic Surgeons,American Association for Thoracic Surgery,American Heart Association,American Society of Nuclear Cardiology,and the Society of Cardiovascular Computed Tomography.J Thorac Cardiovasc Surg,2012,143(4):780-803.
• [14]Windecker S,Kolh P,Alfonso F,et al.2014 ESC/EACTS Guidelines on myocardial revascularization:the task force on myocardial revascularization of the European Society of Cardiology(ESC)and the European Association for CardioThoracic Surgery(EACTS)developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI).Eur Heart J,2014,35(37):2541-619.